@ Newsroom | SEBIO

AGTC Selected as Top Company in the University of Florida’s 2017 Gator100

Posted by on Feb 13, 2017 in Newsroom | 0 comments

GAINSVILLE, FL. & CAMBRIDGE, MA. – Applied Genetic Technologies Corporation (AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that the company has been selected as the top company in the 2017 Gator100 awards. The Gator100, named after the University of Florida’s mascot, recognizes and celebrates the 100 fastest-growing businesses in the world that are either owned or led by University of Florida graduates. The annual award is sponsored by the...

Read More

Biscayne Announces Formation of Biscayne Neurotherapeutics and Completion of Series B Financing

Posted by on Jan 31, 2017 in Newsroom | 0 comments

MIAMI, FL. – Biscayne Neurotherapeutics, Inc., a clinical-stage company established by Biscayne Pharmaceuticals to develop its biopharmaceutical assets for the treatment of neurological disorders, today announced completion of a $3 million Series B financing  The financing was led by the Global Health Sciences Fund of Quark Venture and GF Securities, along with Mesa Verde Venture Partners. Existing Biscayne Pharmaceuticals investors and new private investors also participated. Biscayne Neurotherapeutics will primarily use the funds to conduct a Phase 1b trial of a new extended release...

Read More

Hammock Pharmaceuticals Targeting Women’s Health with Novel Drug Delivery

Posted by on Jan 28, 2017 in Newsroom | 0 comments

CHARLOTTE, N.C. – A new pharmaceutical company has started up in Charlotte to develop and commercialize novel products for women’s health and urology. Hammock Pharmaceuticals is using a novel drug-delivery technology to improve the effectiveness of traditional medicines for a variety of conditions, starting with bacterial vaginosis, a common infection caused by an over-abundance of bacteria in the vagina. More than 21 million women suffer from bacterial vaginosis in the U.S. The company this month announced a license agreement with MilanaPharm and its sister company, TriLogic Pharma,...

Read More

Akron Biotechnology, LLC Partners in New Manufacturing USA Institute

Posted by on Jan 28, 2017 in Newsroom | 0 comments

BOCA RATON, FL. – Akron Biotechnology, LLC (Akron Biotech) is part of a new public-private Manufacturing USA initiative, the Advanced Regenerative Manufacturing Institute (ARMI). Headquartered in Manchester, New Hampshire, ARMI is the 12th Manufacturing USA institute. It brings together a consortium of nearly 100 partner organizations from industry, government, academia and the non-profit sector to develop next-generation manufacturing processes and technologies for cells, tissues and organs. Approximately $80 million from the federal government will be combined with more than $200...

Read More

AGTC and Bionic Sight Announce Strategic Collaboration to Develop an Optogenetic Therapy and Device for Visual Deficits and Blindness

Posted by on Jan 25, 2017 in Newsroom | 0 comments

GAINESVILLE, FL., NEW YORK, NY. and CAMBRIDGE, MA. – Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it has entered into a strategic research and development collaboration with Bionic Sight, an innovator in the emerging field of optogenetics and retinal coding. Through the AGTC-Bionic Sight collaboration, the companies seek to develop a new optogenetic therapy that leverages AGTC’s deep experience in gene...

Read More

Generex Announces Deal to Acquire Controlling Equity Interest in Emmaus Life Sciences, Inc.

Posted by on Jan 24, 2017 in Newsroom | 0 comments

MIRAMAR, FL. – Generex Biotechnology Corporation (OTCPink:GNBT) is pleased to announce that on January 16, 2017 it entered into a letter of intent (the “LOI”) for the acquisition of a controlling equity interest in Emmaus Life Sciences, Inc. (www.emmauslifesciences.com) (“Emmaus”). The Company filed a Form 8-K Current Report in respect of the LOI with the U.S. Securities and Exchange Commission (SEC) (www.sec.gov) on Friday, January 20, 2017. That 8-K provides comprehensive and detailed descriptions of the transaction terms. Emmaus, headquartered in Torrance, CA, is a...

Read More